MARKET NEWS

Spero Therapeutics Announces Positive Topline Results From Phase 1 Bronchoalveolar Lavage Clinical Trial 
Rhythm Pharmaceuticals Announces Positive Interim Data From Long-Term Extension Study 
Revive Therapeutics Receives FDA Orphan Drug Designation
Catalent Expands Temperature-Controlled Clinical Supply Capabilities in Shanghai, China
BioXcel Therapeutics Presents Positive Data From Phase 2 Trial of BXCL701 in Aggressive Forms of Prostate Cancer
Neurocentria Obtains FDA Approval to Conduct Pivotal Phase 2b/3 Clinical Trial for Testing Safety & Efficacy of Drug Candidate NRCT-101SR in Adults With ADHD

  FEATURED EDITORIAL

 

  COMPANY PROFILE

BIOVECTRA is a global biotech and pharmaceutical CDMO that specializes in clinical-to-commercial scale production capabilities for: biologics, bioreagents, fermented small molecules, synthetic small molecules, and active pharmaceutical ingredients. Flexibility, creativity, process optimization and compliance are at the heart of our method. With more than 50 years of experience, 550+ employees, and cGMP facilities in Prince Edward Island and Nova Scotia, Canada we assure our programs advance on time and with the highest quality outcomes. Click here for more.

  EXCLUSIVE ONLINE CONTENT

 

Hillstream BioPharma Receives Orphan Drug Designation for Uveal Melanoma Treatment

Hillstream BioPharma Receives Orphan Drug Designation for Uveal Melanoma Treatment

Hillstream BioPharma Inc. recently announced the FDA granted Orphan Drug Designation to HSB-1216 for Uveal Melanoma (UM). Hillstream continues to….

Adial Pharmaceuticals Announces Closing of  Million Financing

Adial Pharmaceuticals Announces Closing of $10 Million Financing

Adial Pharmaceuticals, Inc. recently announced the closing of its previously announced registered direct offering, whereby a single accredited institutional investor purchased approximately….

Skye Bioscience Reports Positive Results for SBI-100 in GLP Toxicology Study

Skye Bioscience Reports Positive Results for SBI-100 in GLP Toxicology Study

Skye Bioscience, Inc. recently announced it has completed a good laboratory practice (GLP) nonclinical toxicology study of its SBI-100 ophthalmic nanoemulsion in support of the company’s….

Zealand Pharma Completes Enrollment in Phase 3 Trial of Dasiglucagon in Children With Congenital Hyperinsulinism

Zealand Pharma Completes Enrollment in Phase 3 Trial of Dasiglucagon in Children With Congenital Hyperinsulinism

Zealand Pharma A/S  recently announced completion of patient enrollment in the second Phase 3-trial, 17103, of dasiglucagon for the treatment of Congenital hyperinsulinism (CHI) in….

Cerevel Therapeutics Announces Positive Topline Results for Darigabat in Phase 1 Clinical Trial in Acute Anxiety

Cerevel Therapeutics Announces Positive Topline Results for Darigabat in Phase 1 Clinical Trial in Acute Anxiety

Cerevel Therapeutics recently announced positive results from its Phase 1 healthy volunteer clinical trial to evaluate darigabat, a novel alpha-2/3/5 selective GABAA receptor positive allosteric modulator….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

March 2 – Transdermal/Topical Delivery
March 9 – Particle Design Technology